Crinetics Pharmaceuticals Inc
$ 33.53
-2.30%
11 Jun - close price
- Market Cap 3,618,708,000 USD
- Current Price $ 33.53
- High / Low $ 34.48 / 32.70
- Stock P/E N/A
- Book Value 12.16
- EPS -5.14
- Next Earning Report 2026-08-06
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.25 %
- ROE -0.39 %
- 52 Week High 57.99
- 52 Week Low 25.83
About
Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapies for rare endocrine diseases and endocrine-related tumors. The company is headquartered in San Diego, California.
Analyst Target Price
$83.14
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-07 | 2026-02-26 | 2025-11-06 | 2025-08-07 | 2025-05-08 | 2025-02-27 | 2024-11-12 | 2024-08-08 | 2024-05-09 | 2024-02-28 | 2023-11-07 | 2023-08-08 |
| Reported EPS | -1.23 | -1.29 | -1.38 | -1.23 | -1.04 | -0.88 | -0.96 | -0.94 | -0.93 | -0.9 | -1.01 | -0.94 |
| Estimated EPS | -1.2 | -1.28 | -1.25 | -1.1 | -0.95 | -0.8919 | -0.91 | -0.86 | -0.81 | -0.86 | -0.88 | -0.85 |
| Surprise | -0.03 | -0.01 | -0.13 | -0.13 | -0.09 | 0.0119 | -0.05 | -0.08 | -0.12 | -0.04 | -0.13 | -0.09 |
| Surprise Percentage | -2.5% | -0.7813% | -10.4% | -11.8182% | -9.4737% | 1.3342% | -5.4945% | -9.3023% | -14.8148% | -4.6512% | -14.7727% | -10.5882% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-06 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -1.23 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: CRNX
2026-06-12 12:39:08
Sector Gamma AS has made a new $5.35 million investment in Crinetics Pharmaceuticals, Inc. (CRNX), acquiring 115,000 shares in the fourth quarter. This move makes Crinetics Pharmaceuticals the 27th largest holding for Sector Gamma, despite a recent 2.3% drop in the stock price. The company's financials show a smaller-than-expected quarterly loss and revenue beat, but analysts still anticipate a full-year loss, and recent insider selling has raised investor caution.
2026-06-12 08:39:08
Crinetics Pharmaceuticals (NASDAQ:CRNX) has received an average "Moderate Buy" rating from brokerages, with an average 1-year price target of $76.13, despite currently trading at $33.53. The company reported a quarterly EPS loss of ($1.23) but exceeded revenue expectations with $10.73 million. Insider selling, including by the CEO, has been noted, while hedge funds hold a significant 98.51% of outstanding shares.
2026-06-11 14:09:51
Citizens Jmp has reaffirmed its "Market Outperform" rating for Crinetics Pharmaceuticals (CRNX), setting a $95 price target that suggests a significant upside, despite the stock recently dropping 3.8% to $33.01. The company's recent quarterly earnings missed EPS estimates slightly but exceeded revenue expectations, showing a substantial year-over-year increase. Various other analysts have issued ratings ranging from "Strong Buy" to "Sell," with a consensus of "Moderate Buy" and an average price target of $76.13 for CRNX.
2026-06-11 10:09:17
Crinetics Pharmaceuticals Inc. (NASDAQ: CRNX) is highlighted as a top AI-driven biotech stock with a strongly bullish consensus sentiment, offering significant upside potential based on a $88.14 target price. The company is set to present new data from its clinical trials for PALSONIFY and atumelnant at ENDO 2026, showcasing progress in treatments for rare endocrine diseases. Despite a recent slight reduction in target price by an analyst, the firm maintained an Outperform rating, underscoring continued confidence in CRNX's pipeline.
2026-06-11 10:09:17
Citizens has reaffirmed its Market Outperform rating and $95.00 price target for Crinetics Pharmaceuticals (NASDAQ:CRNX), citing the strong launch performance of its drug, Palsonify. The firm views a competitor's manufacturing issues as an incremental positive for Crinetics, reinforcing Palsonify's advantage due to its oral convenience and efficacy. Crinetics reported $10 million in Palsonify sales in Q1 2026 and robust revenue growth, with analysts anticipating continued sales growth this year.
2026-06-10 14:39:08
GW&K Investment Management LLC significantly increased its stake in Crinetics Pharmaceuticals (NASDAQ:CRNX) during the fourth quarter, purchasing an additional 625,779 shares, bringing their total to 1.48 million shares valued at approximately $68.7 million. This move is part of broader institutional interest, with hedge funds collectively owning 98.51% of the company's stock. Despite a recent earnings miss, analysts maintain a "Moderate Buy" rating with an average price target of $76.13 for CRNX.
